Soluble C-type lectin-like receptor 2 in stroke (CLECSTRO) study: protocol of a multicentre, prospective cohort of a novel platelet activation marker in acute ischaemic stroke and transient ischaemic attack

Shinichiro Uchiyama, Katsue Suzuki-Inoue, Hideo Wada, Yasushi Okada, Teruyuki Hirano, Takehiko Nagao, Hiroyuki Kinouchi, Ryotaro Itabashi, Haruhiko Hoshino, Koichi Oki, Yutaka Honma, Nobuo Ito, Hiroshi Sugimori, Masahide Kawamura

ABSTRACT

Introduction Soluble C-type lectin-like receptor 2 (sCLEC-2) is a novel biomarker for platelet activation, which can be easily measured by usual blood collection. We conducted the CLECSTRO, a prospective, observational cohort study, to evaluate the clinical implications of sCLEC-2 in patients with acute ischaemic stroke (AIS) and transient ischaemic attack (TIA).

Methods and analysis The participants are patients with AIS/TIA and control patients required for differentiation from AIS/TIA. The target population is 600, including the patients and controls, who would be recruited from eight stroke centres across Japan. The inclusion criteria are AIS within 24 hours of onset and a modified Rankin Scale (mRS) score of 0–2, TIA within 7 days of onset, and contemporary patients required for differentiation from AIS/TIA. Plasma sCLEC-2 will be measured by high-sensitive chemiluminescent enzyme immunoassay using residual blood samples from routine laboratory examinations at the first visit in all patients and 7 days later or at discharge in patients with AIS/TIA. The outcomes include plasma levels of sCLEC-2 in patients with AIS/TIA and controls, sCLEC-2/D-dimer ratio in non-cardioembolic and cardioembolic AIS/TIA, correlation of sCLEC-2 with recurrence or worsening of stroke, severity of stroke, infarct size, ABCD2 score in TIA and outcome (mRS) at 7 days and 3 months.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ This study is the first multicentre, prospective, observational cohort for soluble C-type lectin-like receptor 2 (sCLEC-2) in patients with acute ischaemic stroke (AIS) and transient ischaemic attack (TIA).

⇒ Measuring sCLEC-2 is expected to be useful for differentiating true AIS and TIA from their mimics and non-cardioembolic AIS/TIA from cardioembolic AIS/TIA, predicting severity and outcome of AIS and TIA, decision-making of antithrombotic therapy, and monitoring antiplatelet therapy.

⇒ sCLEC-2 can be measured rapidly by easy collection of residual blood in routine clinical practice, and thus expected broad application in the frontline of AIS and TIA.

⇒ It is difficult to recruit contemporary patient controls, who must be diagnosed with AIS or TIA mimics, to achieve the target population during the planned recruitment period. If the target population is not achieved, we may have to extend the end of recruitment.

INTRODUCTION

Background Platelet function tests conducted to date include platelet aggregometry, measurement of platelet-specific proteins, such as β-thromboglobulin and platelet factor 4, point-of-care testing, such as Verify Now, and measurement of the expression or binding of adhesion molecules on platelets using flow cytometry. However, these tests are limited by concerns about reproducibility, rapidity, economic performance and simplicity. Therefore, they have not been widely used in clinical practice.

for patients with acute ischaemic stroke (AIS) or transient ischaemic attack (TIA).

**C-type lectin-like receptor 2**
Soluble C-type lectin-like receptor 2 (sCLEC-2) is a new marker for platelet activation that can be easily measured by usual blood collection. Plasma levels of sCLEC-2 have been studied for elucidating the correlations with various thrombotic and inflammatory diseases. Plasma sCLEC-2 levels were reported to be associated with death, poor outcome, severity, disease risk, regulation of inflammatory response, neovascularisation, and tumour growth and metastasis in patients with ischaemic stroke, head trauma, atherosclerosis, deep vein thrombosis, sepsis and cancer. Additionally, in patients with disseminated intravascular coagulation and traumatic brain injury, survivors showed lower levels of sCLEC-2 than non-survivors.

**Study aims**
This study aims to investigate whether sCLEC-2 is useful for differentiating true AIS or TIA from AIS or TIA mimics, classifying AIS and TIA subtypes, decision-making of anti-thrombotic therapy (selection of antiplatelet or anticoagulant therapy), monitoring antiplatelet therapy, and predicting severity and outcome, in order to contribute to the progress of precision medicine in the diagnosis and management of AIS and TIA.

**METHODS AND ANALYSIS**

**Study design, organisation and recruitment of participants**
The CLECSTRO is a multicentre, prospective cohort study in eight stroke centres across Japan (online supplemental table), which adheres to the Strengthening the Reporting of Observational Studies in Epidemiology guidelines. The study organisation is shown in online supplemental table. Recruitment of patients started on 11 October 2022, and will end on 1 December 2023. The study will be terminated on 31 December 2024.

**Inclusion/exclusion criteria and outcome measures**
Flow chart of the CLECSTRO study is shown in figure 1. Inclusion and exclusion criteria are listed in box 1. AIS was defined as the abrupt onset of focal neurological deficits with responsible lesions in the brain, which was confirmed on brain MRI or CT. TIA was defined as a transient episode of focal neurological symptoms such as hemiparesis, hemi-sensory deficit, aphasia, hemianopia or monocular blindness, which meet the criteria by the National Institute of Neurological Diseases III (NINDS III) and without responsible lesions on brain MRI or CT.

**Box 1 Inclusion and exclusion criteria**

**Inclusion criteria:**
1. ≥20 years of age.
2. Male or female.
3. Inclusion criteria by group.
Patient group: patients with ischaemic stroke within 24 hours of onset and modified Rankin Scale score of 0–2 before the onset or transient ischaemic attack within 7 days days after the onset. Control group: contemporary patients presenting with neurological symptoms, requiring differentiation from ischaemic stroke or transient ischaemic attack and subsequently ruled out by the final diagnosis at discharge.

**Exclusion criteria:**
1. Concomitant conditions that may affect platelets or blood coagulation, such as acute thrombosis of other organs, haematological disorders or pregnancy.
2. Cerebral haemorrhage, subarachnoid haemorrhage, traumatic brain injury, other trauma, postoperative cases and bleeding disorders.
3. Severe infectious disease.
4. Patients whose onset time is unknown except for those for whom the onset occurred during sleep.
5. Patients who are deemed inappropriate for this study by a physician.
6. Inadequate condition of the collected specimens.
worsening or recurrence, (3) plasma sCLEC-2/D-dimer ratios in cardiogenic and non-cardiogenic AIS/TIA classified by the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification for comparison between the two groups and (4) correlation of the plasma levels of sCLEC-2 on admission with the modified Rankin Scale (mRS) score at discharge and 3 months following the onset of AIS/TIA. The secondary outcome measures are (1) correlations of sCLEC-2 levels on admission with stroke severity (National Institutes of Health Stroke Scale, NIHSS), size of the infarct, and ABCD² score in TIA and (2) plasma levels of sCLEC-2 in patients with TOAST subtypes of AIS for comparison of intergroup differences. To validate the diagnostic ability of biomarkers statistically, receiver operating characteristic curve (ROC) analysis will be performed, and sensitivity and specificity at appropriate cut-off values will be determined.

These data will be used for marketing authorisation application to the Pharmaceuticals and Medical Devices Agency for the reagent coded LM22-01, a reagent for determining sCLEC-2.

Sample size calculation
The target number of patients is 600, including 400 patients with AIS, 100 with TIA and 100 control patients. The minimum sample size of cardiogenic or non-cardiogenic AIS is 81 for each group when the sensitivity and specificity are 70%, the level of significance is 5% and the L value is 0.1 in analysing the diagnostic performance. When patients with cardiogenic AIS were estimated to be approximately 25% of all patients with AIS, the number of AIS was set as 400 so that approximately 100 patients with cardiogenic AIS would be included (to ensure a minimum of 81 patients is reached). For the TIA and control groups, the minimum sample size is 81 when the sensitivity and specificity are both 70%, the level of significance is 5% and the L value is 0.1 in analysing the diagnostic performance. The target number of patients in both groups was set at 100 to ensure that more than 81 patients would be included. If the planned analysis changes after database locking, the justification will be described in the completed report.

Measurement of C-type lectin-like receptor 2
The conditions for blood collection in this study were in accordance with recommendations for sample preparation for clotting time of the Japanese Society of Laboratory Haematology, which were based on the Clinical and Laboratory Standards Institute H21-A5. Residual blood samples from routine laboratory examinations will be used at the first visit, 7±1 days later and possibly at the time of discharge from patients with AIS or TIA. For the patients in the control group, residual blood samples will be used only during the first visit. Plasma sCLEC-2 will be measured by high-sensitive chemiluminescent enzyme immunoassay (CLEIA). We have previously confirmed that ELISA detected shed and platelet-derived extracellular vesicle types using ultracentrifuge fractionation. Shed type and extracellular vesicle type were separated by ultracentrifugation and detected by Western blotting. We will use the same combination of monoclonal antibodies in sCLEC-2 CLEIA reagents for this study.

Soluble fibrin, thrombin-antithrombin complex and D-dimer levels will be measured simultaneously in these samples.

Baseline and follow-up data
Baseline characteristics, including age, sex, hypertension, diabetes, dyslipidaemia, current cigarette smoking, habitual alcohol drinking, atrial fibrillation, history of stroke, myocardial infarction, peripheral artery disease, chronic kidney disease and use of antiplatelet drugs or anticoagulants, will be documented. Body weight, body mass index, systolic and diastolic blood pressure, complete blood count, liver enzymes, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, triglyceride, blood glucose, haemoglobin A1c, creatinine, uric acid, C-reactive protein and brain natriuretic peptide (BNP) or NTpro BNP will also be recorded.

The NIHSS and mRS scores will be assessed on admission, at 7 days or at discharge and at 3 months after the onset. The sizes of infarcts on diffusion-weighted MRI would be classified into small, large and medium infarcts. Small infarcts are defined as <2cm, large infarcts as a half or more in the middle cerebral artery territory and medium infarcts as sizes between small and large infarcts.

Data will be entered by investigators into Case Report Form and reviewed by the principal investigator and the investigators in the stroke centres. After confirming that there are no omissions or errors in the content, the principal investigator will sign and complete the case report.

Statistical analysis
Statistical analyses are as follows. In the comparison between the two groups, the normal distribution in each group will be evaluated using the Kolmogorov-Smirnov test. When a normal distribution is observed, Welch’s test will be used, whereas when a normal distribution is not observed, the logarithmic transformation will be performed. If a normal distribution is observed after the logarithmic transformation, Welch’s test will be used for values after the logarithmic transformation. When a normal distribution is not observed even after the logarithmic transformation, the Mann-Whitney U test will be used. The Dunnett’s, Steel-Dwass, Tukey’s or Kruskal-Wallis test will be used for comparisons of three or more groups. To validate the diagnostic ability of biomarker results statistically, ROC analysis will be performed to calculate, and sensitivity and specificity at appropriate cut-off values will be determined. Correlations between two variables will be assessed using Pearson’s or Spearman’s correlation coefficient. Data with missing values for the variables necessary in the analyses will be excluded from the analysis dataset. The level of statistical significance is set at p<0.05. Multivariate regression analyses will be
used for analyses assessing confounding factors possibly affecting the outcomes, which were selected from background variables by univariate regression analysis. All the statistical analyses will be performed using StatFlex V.7 (Artec, Osaka, Japan).

**Patients and public involvement**

Participants and the public were neither involved in the study design, recruitment, or conduct nor the selection of research questions or study outcomes. All research facilities of the CLECSTRO team post the significance and content of this research on their respective websites and are actively working to make this research known. The CLECSTRO team is fully aware of and committed to the importance of involving the public as active stakeholders in its research activities. We aim to submit the research results to the Japanese authorities (Pharmaceuticals and Medical Devices Agency) for approval as a diagnostic reagent for sCLEC-2. CLECSTRO researchers take the lead in diverse research-related communications and public awareness initiatives aimed at increasing awareness about AIS/TIA as well as the ongoing development of sCLEC-2.

**ETHICS AND DISSEMINATION**

This study was approved by the Ethical Committee of the University of Yamanashi (CS0011) as the central ethical committee in agreement with the ethical committees of all collaborative stroke centres. Informed consent will be obtained by an opt-out form from the patients at each stroke centre according to the Ethical Guidelines for Medical and Biological Research Involving Human Subjects by the Japanese Ministry of Health, Labour and Welfare. Written informed consent will not be obtained due to the measurement in blood samples collected from residual blood in usual clinical practice; however, detailed information about the study has been made available on a website to ensure that participants are fully informed and have the option to decline participation. The research secretariat confirmed compliance with opt-out procedures at each study site according to the guidelines. The results of this study will be presented at international and domestic conferences and submitted for publication in peer-reviewed journals.

**DISCUSSION**

CLEC-2 is a platelet receptor for podoplanin, which is expressed on certain types of tumour and lymphatic endothelial cells (figure 2). The CLEC-2/podoplanin interaction facilitates tumour metastasis, blood/lymphatic vessel separation and normal lung formation during embryonic development. sCLEC-2 is released from platelets activated by agonists, such as collagen and thrombin; thus, it can be considered a new biomarker for platelet activation.

Figure 2  Mechanism of platelet activation by CLEC-2. Btk, Bruton’s tyrosine kinase; CLEC-2, C-type lectin-like receptor 2; DG, diacyl-glycerol; IP3, inositol 1,4,5-trisphosphate; LAT, linker for activation of T cells; PIP2, phosphatidylinositol 4,5-bisphosphate; PLCγ2, phospholipase Cγ2; Syk, spleen tyrosine kinase; SLP-76, SH2 domain-containing leukocyte phosphoprotein of 76 kDa. Rhodocytin is a snake venom and an external ligand of CLEC-2.

In CLEC-2-deficient mice prepared by the administration of the anti-CLEC-2 antibody, which can abolish CLEC-2 in plasma, platelet adhesion was reported to be preserved; however, platelet aggregation did not occur, and thus the bleeding time was prolonged, and arterial obstruction was not induced.

Suzuki-Inoue’s group and LSI Medience Corporation have established the method to measure sCLEC-2 by ELISA and CLEIA using anti-CLEC-2 antibodies. The CLEIA method can detect sCLEC-2 with high sensitivity, which can be measured using usual citrated blood in routine clinical practice. When platelets are activated, sCLEC-2 in plasma is measured as a shed form of 25 kDa molecule, and 32 kD and 40 kD molecules bound to extracellular vesicles released from the platelets, which was confirmed by ELISA and Western blotting using the same combination of monoclonal antibodies as CLEIA.

The relationship between sCLEC-2 and several diseases has been reported in disseminated intravascular coagulation, thrombotic microangiopathy, COVID-19, traumatic brain injury, venous thromboembolism, and acute coronary syndrome. However, it should be elucidated whether sCLEC-2 can be a predictor of outcomes in these diseases by prospective observational studies. sCLEC-2 was reported to be a predictor of death or vascular events in patients with ischaemic stroke and was associated with stroke progression and outcome. The plasma levels of sCLEC-2 were also reported to be higher in patients with AIS, TIA and acute myocardial infarction than in healthy controls and those with deep vein thrombosis, syncope, gastrointestinal disease, heart failure, anaemia, thrombotic thrombocytopenic purpura and indefinite compliant syndrome. Additionally, in this study, the plasma levels of sCLEC-2 were higher in patients with atherothrombotic or lacunar stroke than in...
those with cardioembolic stroke, while the D-dimer level was higher in patients with cardioembolic stroke than in those with atherothrombotic or lacunar stroke; hence, sCLEC-2/D-dimer ratios were higher in atherothrombolytic or lacunar stroke than in those with cardioembolic stroke, which suggests that sCLEC-2/D-dimer ratio is useful for the differential diagnosis of non-cardioembolic stroke (platelet-dependent disease state) and cardioembolic stroke (thrombin-generated disease state). D-dimer was reported to be higher in patients with cardioembolic stroke than in those with other subtypes of AIS, and we reported that platelet activation markers such as beta-thromboglobulin and platelet factor 4 were more pronounced in atherothrombolytic stroke. Therefore, we inferred that the sCLEC-2/D-dimer ratio can be a sensitive marker for differentiating cardioembolic AIS/TIA from non-cardioembolic AIS/TIA, which was suggested in the previous report.

The CLE CSTRO study is the first multicentre, prospective, observational cohort of patients with AIS and TIA across Japan. This study aims to investigate whether sCLEC-2 is useful for differentiating true AIS or TIA from AIS or TIA mimics, classifying AIS and TIA subtypes, decision-making of antithrombotic therapy (selection of antiplatelet or anticoagulant therapy), monitoring antiplatelet therapy, and predicting severity and outcome. sCLEC-2 has the potential to serve as a novel and broadly applicable biomarker, thereby contributing to the progress of precision medicine in the pathophysiology, diagnosis, and management of AIS and TIA.

Author affiliations
1Clinical Research Center for Medicine, International University of Health and Welfare, Tokyo, Japan
2Department of Clinical and Laboratory Medicine, University of Yamashini, Chuo, Japan
3Department of General and Laboratory Medicine, Mie Prefectural General Medical Centre, Yokkaichi, Japan
4Department of Cerebrovascular Medicine and Neurology, National Hospital Organization Kyushu Medical Centre, Fukuoka, Japan
5Department of Stroke and Cerebrovascular Medicine, Kyorin University, Mitaka, Japan
6Department of Neurology, Nippon Medical School Musashikosugi Hospital, Kawasaki, Japan
7Department of Neurosurgery, University of Yamashini, Chuo, Japan
8Division of Neurology & Gerontology, Uwate Medical University, Shioa, Japan
9Department of Neurology, Tokyo Saiseikai Central Hospital, Tokyo, Japan
10Department of Neurology, Showa General Hospital, Kuida, Japan
11Department of Neurology, Mie Prefectural General Medical Centre, Yokkaichi, Japan
12Department of Research and Development, LSI Medience Corporation, Tokyo, Japan

Contributors
SU planned the study, designed the protocol, wrote the original draft of the manuscript and revisions, and chaired the protocol and publication committees as the study chair. KS-I applied the protocol to and obtained approval from the central ethical committee, registered the study to ClinicalTrials.gov and UMIN as the principal investigator, and revised the manuscript. MK acquired funding from LSI Medience Corporation, reviewed and revised the protocol and the manuscript, and submitted the manuscript. HW, YO, TH and TN discussed the study plan and reviewed and revised the protocol and the manuscript as members of the protocol and publication committees. HK, RH, HH, KO, YH, Nl and HS reviewed the manuscript and are participating in recruiting patients, template recording, management of blood collection, storing and measurement as the heads or the responsible investigators of the institutions.

Funding
The authors disclosed receipt of the financial support for the research, authorship, and publication of this article from LSI Medience Corporation.

Competing interests
SU reports consultant fees from LSI Medience Corporation. KS-I has a patent related to the sCLEC-2 assay (JP-6078843). MK is an advisor of LSI Medience Corporation. HW and MK are inventors of a patent application related to sCLEC-2 measurement in AIS and TIA (JP application 2021-091606).

Patient and public involvement
Patients and/or the public were involved in the design, or conduct, or reporting, or dissemination plans of this research. Refer to the Methods section for further details.

Patient consent for publication
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Shinichiro Uchiyama http://orcid.org/0000-0002-8260-8190
Katsue Suzuki-Inoue http://orcid.org/0000-0001-3678-1451
Hideo Wada http://orcid.org/0000-0001-9821-9333
Yuasa Okada http://orcid.org/0000-0002-3150-6157
Teruyuki Hirano http://orcid.org/0000-0003-2094-2428
Takehiko Nagao http://orcid.org/0000-0001-5289-2467
Hiroaki Kinouchi http://orcid.org/0000-0003-0841-5502
Ryo Ishibashi http://orcid.org/0000-0001-8096-457X
Haruhiko Hoshino http://orcid.org/0000-0001-8151-3796
Koichi Oki http://orcid.org/0000-0003-2640-3337
Yutaka Honma http://orcid.org/0000-0002-0609-7769
Nobuo Ito http://orcid.org/0000-0001-6549-8880
Hiroshi Sugimoto http://orcid.org/0000-0002-1135-1653
Masahide Kawamura http://orcid.org/0000-0002-9495-2314

REFERENCES
7 Easton JD, Saver JL, Albers GW, et al. Definition and evaluation of transient ischemic attack: A scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary


